Organisation paid for research Program year 2025 Source: CMS Open Payments

BoganSleep Consultants, LLC

Neither a doctor nor a teaching hospital

Research payments

$131,450

14 payments

Through program year 2025, BoganSleep Consultants, LLC is reported as receiving $131,450 in research payments, across 14 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $19,385 1
2024 Research $5,000 1
2023 Research $13,594 2
2021 Research $93,472 10

Breakdown

Who paid Research payments · program years 2021–2025
  1. Jazz Pharmaceuticals Inc. $101,283 11 payments
  2. Idorsia Pharmaceuticals US Inc $30,167 3 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 4 Multicenter, Open-Label, Single-Arm Study of Safety, Tolerability, Effectiveness and Treatment Optimization in Participants Switching From Xyrem to Xywav for the Treatment of Narcolepsy $71,311 9 payments
  2. Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder $24,385 2 payments
  3. A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of Jzp-258 in the Treatment of Idiopathic Hypersomnia (Ih) With An Open-Label Safety Extension $23,522 1 payment
  4. Solriamfetols Effect on Cognitive Health in Apnea Participants During A Randomized Placebo Controlled Study: A 5 Week Double Blind, Placebo Controlled, Randomized, Crossover, Multicenter Study of Solriamfetol in Improving Cognitive Function in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Plus Impaired Cognitive Function $6,450 1 payment
  5. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Polysomnography, Dose-Finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-Dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder $5,782 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record